Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.
10.4111/kju.2013.54.9.631
- Author:
Ui Jae SHIM
1
;
Il Seok LEE
;
Ho Won KANG
;
Jayoung KIM
;
Won Tae KIM
;
Isaac Yi KIM
;
Keun Ho RYU
;
Yung Hyun CHOI
;
Sung Kwon MOON
;
Yong June KIM
;
Seok Joong YUN
;
Sang Cheol LEE
;
Wun Jae KIM
Author Information
1. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. wtkimuro@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Bladder cancer;
Human DBC1 protein;
Prognosis
- MeSH:
Chromosomes, Human, Pair 9;
Genes, Tumor Suppressor;
Humans;
Kaplan-Meier Estimate;
Loss of Heterozygosity;
Mucous Membrane;
Prognosis;
Real-Time Polymerase Chain Reaction;
Recurrence;
Urinary Bladder;
Urinary Bladder Neoplasms
- From:Korean Journal of Urology
2013;54(9):631-637
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The deleted in bladder cancer 1 (DBC1) gene is located within chromosome 9 (9q32-33), a chromosomal region that frequently shows loss of heterozygosity in bladder cancer (BC). It is suspected that it acts as a tumor suppressor gene, but its prognostic value remains unclear. The aim of the present study was to investigate the value of DBC1 as a prognostic marker in BC. MATERIALS AND METHODS: The expression of DBC1 was determined by real-time polymerase chain reaction analysis in 344 patients with BC (220 non-muscle-invasive BC [NMIBC] and 124 muscle-invasive BC [MIBC]) and in 34 patients with normal bladder mucosa. The results were compared with clinicopathologic parameters, and the prognostic value of DBC1 was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model. RESULTS: DBC1 expression was significantly decreased in patients with MIBC compared with those diagnosed with NMIBC (p=0.010). Patients with aggressive tumor characteristics had lower DBC1 expression levels in NMIBC (each, p<0.05). By multivariate Cox regression analysis, low DBC1 expression was a predictor of progression to MIBC (hazard ratio, 7.104; p=0.013). Kaplan-Meier estimates revealed a significant difference in tumor recurrence, progression to MIBC, and cancer-specific survival depending on the level of DBC1 expression in NMIBC (log-rank test, each, p<0.05). CONCLUSIONS: The expression of DBC1 was associated with tumor aggressiveness, progression to MIBC, and survival in NMIBC. Our results suggest that DBC1 expression can be a useful prognostic marker for patients with NMIBC.
